Tianjin Chase Sun Pharmaceutical Co.,Ltd

SZSE:300026 Stock Report

Market Cap: CN¥11.4b

Tianjin Chase Sun PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 5/6

Tianjin Chase Sun PharmaceuticalLtd has a total shareholder equity of CN¥9.0B and total debt of CN¥803.8M, which brings its debt-to-equity ratio to 9%. Its total assets and total liabilities are CN¥11.4B and CN¥2.4B respectively. Tianjin Chase Sun PharmaceuticalLtd's EBIT is CN¥171.9M making its interest coverage ratio 5. It has cash and short-term investments of CN¥1.1B.

Key information

9.0%

Debt to equity ratio

CN¥803.83m

Debt

Interest coverage ratio5x
CashCN¥1.12b
EquityCN¥8.96b
Total liabilitiesCN¥2.41b
Total assetsCN¥11.37b

Recent financial health updates

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

Nov 22
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Recent updates

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

Nov 22
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Nov 01
We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

Sep 26
Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Jun 12
There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

May 22
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

May 21
This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04
Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Financial Position Analysis

Short Term Liabilities: 300026's short term assets (CN¥6.3B) exceed its short term liabilities (CN¥1.7B).

Long Term Liabilities: 300026's short term assets (CN¥6.3B) exceed its long term liabilities (CN¥741.8M).

Debt to Equity History and Analysis

Debt Level: 300026 has more cash than its total debt.

Reducing Debt: 300026's debt to equity ratio has increased from 3.4% to 9% over the past 5 years.

Debt Coverage: 300026's debt is well covered by operating cash flow (129.7%).

Interest Coverage: 300026's interest payments on its debt are well covered by EBIT (5x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 17:44
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Chase Sun Pharmaceutical Co.,Ltd is covered by 20 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xin ZhangAJ Securities Co., Ltd
Wen Wen ShenAvic Securities Co., Ltd
Yalei YanBohai Securities Co., Ltd.